538 related articles for article (PubMed ID: 18367459)
1. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
[TBL] [Abstract][Full Text] [Related]
2. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
Tuon FF; Rymsza AM; Penteado-Filho SR; Pilonetto M; Arend LN; Levin AS
J Infect; 2011 Mar; 62(3):246-9. PubMed ID: 21256151
[No Abstract] [Full Text] [Related]
3. Outcomes and appropriateness of management of nosocomial Acinetobacter bloodstream infections at a teaching hospital in northeastern Malaysia.
Deris ZZ; Harun A; Shafei MN; Rahman RA; Johari MR
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):140-7. PubMed ID: 19323046
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
Jain R; Danziger LH
Ann Pharmacother; 2004 Sep; 38(9):1449-59. PubMed ID: 15280512
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk factors of Acinetobacter baumannii bacteraemia.
Choi JY; Park YS; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YA; Song YG; Yong D; Lee K; Kim JM
Intern Med J; 2005 Oct; 35(10):599-603. PubMed ID: 16207259
[TBL] [Abstract][Full Text] [Related]
7. How carbapenem-resistant Acinetobacter spp. established in a newly constructed hospital.
Lu PL; Huang LY; Lian ST; Chang K; Lin CL; Hwang IJ; Chiang WG; Chen YH; Lin SF; Siu LK
Int J Antimicrob Agents; 2008 May; 31(5):463-6. PubMed ID: 18359613
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection.
Vitkauskiene A; Dambrauskiene A; Cerniauskiene K; Rimdeika R; Sakalauskas R
Scand J Infect Dis; 2013 Mar; 45(3):213-8. PubMed ID: 23113773
[TBL] [Abstract][Full Text] [Related]
10. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital.
Aydemir H; Celebi G; Piskin N; Oztoprak N; Keskin AS; Aktas E; Sumbuloglu V; Akduman D
Jpn J Infect Dis; 2012; 65(1):66-71. PubMed ID: 22274161
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments.
Rodríguez Guardado A; Blanco A; Asensi V; Pérez F; Rial JC; Pintado V; Bustillo E; Lantero M; Tenza E; Alvarez M; Maradona JA; Cartón JA
J Antimicrob Chemother; 2008 Apr; 61(4):908-13. PubMed ID: 18281693
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
Metan G; Sariguzel F; Sumerkan B
Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.
Tong W; Wang R; Chai D; Li Z; Pei F
Int J Antimicrob Agents; 2006 Nov; 28(5):454-6. PubMed ID: 16987639
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter.
Kim YA; Choi JY; Kim CK; Kim CO; Kim MS; Choi SH; Chin BS; Han SH; Lee HS; Choi HK; Jeoung SJ; Song YG; Yum JH; Yong D; Lee K; Kim JM
Scand J Infect Dis; 2008; 40(3):234-40. PubMed ID: 17852898
[TBL] [Abstract][Full Text] [Related]
18. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection.
del Mar Tomas M; Cartelle M; Pertega S; Beceiro A; Llinares P; Canle D; Molina F; Villanueva R; Cisneros JM; Bou G
Clin Microbiol Infect; 2005 Jul; 11(7):540-6. PubMed ID: 15966971
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
